Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.45 |
| ▸ | LIPG | Q9Y5X9 | 13/20 | 0.41 |
| ▸ | LPL | P06858 | 12/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.41 |
| ▸ | F11 | P03951 | 1/20 | 0.38 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.36 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.36 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3796751 | 0.89 | CHRNB2 (0.37) | LIPGLPLF11DGAT1CHRNB2 | |
| SCHEMBL3801108 | 0.86 | LIPG (0.45) | LIPGLPLTAAR1DGAT1CHRNB2 | |
| SCHEMBL3792923 | 0.85 | DGAT1 (0.42) | HRH3LIPGLPLF11DGAT1 | |
| SCHEMBL3803519 | 0.84 | MKNK1 (0.45) | LIPGLPLF11DGAT1 | |
| SCHEMBL551592 | 0.83 | CHRNB2 (0.41) | LIPGLPLF11DGAT1CHRNB2 | |
| SCHEMBL3802884 | 0.82 | NOS3 (0.42) | LIPGLPLF11DGAT1 | |
| SCHEMBL3796814 | 0.81 | LIPG (0.37) | LIPGLPLF11DGAT1 | |
| SCHEMBL1908908 | 0.79 | LIPG (0.66) | LIPGLPL | |
| SCHEMBL3796275 | 0.79 | LIPG (0.62) | LIPGLPLDGAT1 | |
| SCHEMBL520826 | 0.78 | LPL (0.61) | HRH3LIPGLPLTAAR1F11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8314112-B2 | Pyrrolopyrimidines and pyrrolopyridines | NOVARTIS AG (CH) | 2012-11-20 | — | — | US | disclosed |
| EP-2242756-A2 | PYRROLOPYRIMIDINES AND PYRROLOPYRIDINES | Novartis AG (CH) | 2010-10-27 | — | — | EP | disclosed |
| US-20090181941-A1 | Pyrrolopyrimidines and Pyrrolopyridines | NOVARTIS AG (CH) | 2009-07-16 | — | — | US | disclosed |
| WO-2009087225-A2 | PYRROLOPYRIMIDINES AND PYRROLOPYRIDINES | NOVARTIS AG (CH) | 2009-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090181941-A1 | Pyrrolopyrimidines and Pyrrolopyridines | ALK, ACVR1, PTPN4 | HRH3 977/4885LIPG 2295/4885LPL 2217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.